Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Net Margin (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Net Margin for 5 consecutive years, with 12.08% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 1270.0% year-over-year to 12.08%, compared with a TTM value of 10.22% through Dec 2025, up 1850.0%, and an annual FY2025 reading of 10.22%, up 1850.0% over the prior year.
  • Net Margin was 12.08% for Q4 2025 at Kiniksa Pharmaceuticals International, up from 10.19% in the prior quarter.
  • Across five years, Net Margin topped out at 226.05% in Q3 2022 and bottomed at 252.53% in Q3 2021.
  • Average Net Margin over 5 years is 18.94%, with a median of 3.3% recorded in 2022.
  • The sharpest move saw Net Margin soared 47858bps in 2022, then tumbled -24671bps in 2023.
  • Year by year, Net Margin stood at 235.15% in 2021, then soared by 99bps to 3.01% in 2022, then skyrocketed by 3392bps to 99.03% in 2023, then crashed by -101bps to 0.62% in 2024, then soared by 2059bps to 12.08% in 2025.
  • Business Quant data shows Net Margin for KNSA at 12.08% in Q4 2025, 10.19% in Q3 2025, and 11.37% in Q2 2025.